Article Text

Download PDFPDF

2022-RA-1191-ESGO Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel in high-risk HPV women over 40: sub-analysis of the paloma clinical trial & papilobs real-life study
  1. Santiago Palacios1,
  2. Javier Cortés2,
  3. Javier de Santiago3 and
  4. Yann Gaslain4
  1. 1Instituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain
  2. 2Private Practice, Palma, Spain
  3. 3Centro Oncológico MD Anderson, Madrid, Spain
  4. 4Procare Health Iberia, Barcelona, Spain


Introduction/Background HPV clearance and resolution of cervical HPV-dependent lesions become difficult in peri and postmenopausal women. The objective of this analysis was to evaluate the effect of the Papilocare®, a multi-ingredient Coriolus versicolor-based vaginal gel in repairing the high-risk (HR) HPV-dependent low-grade cervical lesions in women over 40 years

Methodology Paloma study ( NCT04002154) was a multicenter, randomized, open-label, parallel-group, watchful waiting approach-controlled clinical trial. Unvaccinated HPV positive women aged between 30–65 with cytology of ASCUS or LSIL and concordant colposcopy image were randomized into 3 groups: A) Papilocare® 1 cannula/day for 1 month + 1 cannula/alternate days for 5 months; B) Papilocare® 1 cannula/day for 3 months + 1 cannula/alternate days for 3 months; C) Control group: watchful waiting approach. Papilobs study ( NCT04199260) was an observational, multicenter, prospective, one-cohort study. Vaccinated or not HPV-positive women aged > 25 y with cytology of ASCUS or LSIL and concordant colposcopy were included. Patients were treated with Papilocare® 1 cannula/day for 21 days during first month + 1 cannula/alternate days for 5 or 11 months. Percentages of patients with normal cytology and concordant colposcopy are presented.

Results A total of 30 and 68 HR-HPV patients above 40yo were evaluated in Paloma and Papilobs studies, respectively. In the Paloma trial, normal cytology and concordant colposcopy was observed in 90% vs 33% patients in A+B Papilocare® and control groups, respectively, (p=0.003, Fisher test). Overall, throughout the Papilobs study normal cytology and concordant colposcopy was achieved in 81.2% patients (73.5% at 6 months).

Abstract 2022-RA-1191-ESGO Figure 1

Conclusion After a 6 month treatment period, Papilocare® showed a clinically robust and statistically significant efficacy in repairing cervical HR-HPV lesions in women over 40 years vs watchful waiting approach. This efficacy was corroborated in the real-life study in more than 2/3 of the HR-HPV patients above 40.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.